Mutations, deletions, or methylation of the VHL gene occur in more than 90% of clear-cell renal-cell carcinoma tumors and result in dysregulation of the hypoxia-inducible factor (HIF) pathway ...

Everolimus (Afinitor, Novartis) is not as effective as sunitinib (Sutent, Pfizer) in the first-line setting for patients with metastatic renal cell carcinoma, and it has a different toxicity ...

Please provide your email address to receive an email when new articles are posted on . CHICAGO — In renal cell carcinoma, adjuvant everolimus improved recurrence-free survival after nephrectomy ...

More information: Belzutifan versus everolimus in participants (pts) with previously treated advanced clear cell renal cell carcinoma (ccRCC): randomized open-label phase 3 LITESPARK-005 study ...

Adjuvant everolimus (Afinitor) failed to significantly improve recurrence-free survival (RFS) in patients with renal cell carcinoma (RCC) who were at high risk for recurrence after nephrectomy ...

This trial compared apitolisib and everolimus for kidney cancer that had spread to another part of the body. It was for people with renal cell cancer (RCC). The trial was open for people to join ...

Everolimus An mTor inhibitor that can be used on its own or in combination with lenvatinib as a second-line therapy for stage 4 renal cell cancer. In a clinical trial of 658 individuals previously ...

A secondary analysis from the SWOG S0931 EVEREST trial has found that in the subgroup of patients with clear-cell renal cell carcinoma ... who were treated with everolimus after surgery had ...

Summary: The LITESPARK-005 phase 3 clinical enrolled 746 patients with metastatic clear cell renal ... or everolimus. Overabundant HIF-2α is associated with increased cancer-driving activity.

Belzutifan improved PFS and objective response compared with everolimus for patients with advanced renal cell carcinoma. Rates of treatment-related grade 3 or higher adverse events appeared ...

Findings from the LITESPARK-005 trial showed a statistically significant improvement in progression free survival with belzutifan compared with everolimus. The Food and Drug Administration (FDA ...

This randomized, open-label, phase 3 trial evaluated the efficacy of cabozantinib, as compared with everolimus, in patients with renal-cell carcinoma that had progressed after VEGFR-targeted therapy.